A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects
Latest Information Update: 25 Jul 2024
At a glance
- Drugs SAB-185 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors SAB BIO; SAB Biotherapeutics
- 20 Jun 2024 According to a SAB Biotherapeutics media release, company name changed from SAB Biotherapeutics to SAB BIO.
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 25 Oct 2021 Planned End Date changed from 1 Jul 2021 to 1 Nov 2021.